Ask AI
FLT3 AML therapy

CME

New Frontiers in FLT3+ AML: Therapeutic Advances in FLT3 Inhibitor Therapy

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: August 29, 2025

Expiration: February 28, 2026

Activity

Progress
1 2 3
Course Completed

How many people with acute myeloid leukemia (AML) do you provide care for in a typical month?

Based on results from the QuANTUM-First trial evaluating quizartinib plus 7+3 vs placebo plus 7+3 in newly diagnosed AML, which of the following patient populations would most likely obtain a significant overall survival (OS) benefit with quizartinib therapy?

In an analysis of relapse-free survival (RFS) outcomes from the double-blind, randomized phase III MORPHO trial comparing gilteritinib vs placebo as posttransplant maintenance therapy in patients with FLT3-ITD–positive AML in first remission, which of the following patient populations showed a significant improvement in RFS with gilteritinib treatment?